Allergan plc (AGN) Quote| Reuters.com
Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

234.02USD
1 Jul 2016
Change (% chg)

$2.93 (+1.27%)
Prev Close
$231.09
Open
$231.78
Day's High
$234.39
Day's Low
$229.76
Volume
2,408,970
Avg. Vol
4,693,070
52-wk High
$340.34
52-wk Low
$195.50

AGN

Chart for AGN

About

Allergan plc, formerly Actavis plc, is a pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products (brand, branded or specialty brand), medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. It operates through... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $92,568.23
Shares Outstanding(Mil.): 395.56
Dividend: --
Yield (%): --

Financials

  AGN Industry Sector
P/E (TTM): -- 35.27 36.15
EPS (TTM): -5.63 -- --
ROI: -1.68 15.09 14.31
ROE: -3.52 16.14 15.51

Impax buys generic drugs from Teva, Allergan for $586 million

Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

Jun 21 2016

UPDATE 2-Impax buys generic drugs from Teva, Allergan for $586 mln

June 21 Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

Jun 21 2016

BRIEF-Impax signs agreements to acquire generic products from Teva, Allergan

* Expects 2016 total company revenues to increase at least 15% over full year 2015

Jun 21 2016

Impax buys portfolio of generic products from Teva, Allergan

June 21 Impax Laboratories Inc said it would buy a portfolio of generic products from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

Jun 21 2016

BRIEF-Allergan says FDA accepts premarket notification filing for glaucoma treatment

* "Look forward to working together with FDA" to bring glaucoma treatment system to market

Jun 15 2016

India's Dr Reddy's in $350 million deal to buy eight U.S. drugs from Teva, Allergan

MUMBAI India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.

Jun 11 2016

CORRECTED-UPDATE 1-India's Dr Reddy's in $350 mln deal to buy 8 U.S. drugs from Teva, Allergan

MUMBAI, June 11 India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.

Jun 11 2016

CORRECTED-India's Dr Reddy's to buy 8 U.S. generic drugs from Teva, Allergan for $350 mln

MUMBAI, June 11 India's No. 2 drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy a portfolio of eight generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for $350 million in cash to bolster its U.S. business.

Jun 11 2016

BRIEF-Allergan says supplemental NDA for 72 mcg Linaclotide accepted for FDA review

* FDA prescription drug user fee act (PDUFA) target action date is expected to occur in early 2017

Jun 09 2016

BRIEF-Allergan CEO to CNBC: "Don't know exactly" how large Icahn's position in the company is

* Allergan CEO to CNBC: "Don't know exactly" how large Icahn's position in the company is

Jun 06 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Validea
$12.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.